Health Care [ 12/12 ] | Pharmaceuticals [ 64/74 ]
NASDAQ | Common Stock
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally.
The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders.
The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders.
The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 31, 24 | 5.30 Increased by +17.52% | 4.77 Increased by +11.11% |
| May 1, 24 | 2.68 Decreased by -32.15% | 4.18 Decreased by -35.89% |
| Feb 28, 24 | 5.02 Increased by +7.27 K% | 5.18 Decreased by -3.09% |
| Nov 8, 23 | 4.84 Decreased by -6.38% | 4.93 Decreased by -1.83% |
| Aug 9, 23 | 4.51 Increased by +4.88% | 4.43 Increased by +1.81% |
| May 10, 23 | 3.95 Increased by +5.90% | 4.24 Decreased by -6.84% |
| Mar 1, 23 | -0.07 Decreased by -101.66% | 0.32 Decreased by -121.88% |
| Nov 9, 22 | 5.17 Increased by +23.10% | 4.66 Increased by +10.94% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 1.05 B Increased by +8.52% | 215.06 M Increased by +46.48% | Increased by +20.38% Increased by +34.98% |
| Jun 30, 24 | 1.02 B Increased by +6.95% | 168.57 M Increased by +61.40% | Increased by +16.46% Increased by +50.92% |
| Mar 31, 24 | 901.98 M Increased by +1.03% | -14.62 M Decreased by -121.06% | Decreased by -1.62% Decreased by -120.84% |
| Dec 31, 23 | 1.01 B Increased by +4.10% | 94.15 M Increased by +139.24% | Increased by +9.30% Increased by +137.70% |
| Sep 30, 23 | 972.14 M Increased by +3.35% | 146.82 M Increased by +958.45% | Increased by +15.10% Increased by +930.64% |
| Jun 30, 23 | 957.32 M Increased by +2.62% | 104.44 M Increased by +201.28% | Increased by +10.91% Increased by +193.59% |
| Mar 31, 23 | 892.81 M Increased by +9.72% | 69.42 M Increased by +1.10 K% | Increased by +7.78% Increased by +992.94% |
| Dec 31, 22 | 972.12 M Increased by +8.41% | -239.95 M Decreased by -578.77% | Decreased by -24.68% Decreased by -526.13% |